AegirBio Past Earnings Performance
Past criteria checks 0/6
AegirBio's earnings have been declining at an average annual rate of -50.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 44.2% per year.
Key information
-50.5%
Earnings growth rate
-23.6%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -44.2% |
| Return on equity | n/a |
| Net Margin | -64,887.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AegirBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -60 | 18 | 42 |
| 30 Sep 23 | 0 | -367 | 20 | 46 |
| 30 Jun 23 | 0 | -362 | 25 | 40 |
| 31 Mar 23 | 0 | -364 | 28 | 41 |
| 31 Dec 22 | 2 | -363 | 28 | 39 |
| 30 Sep 22 | 3 | -88 | 40 | 49 |
| 30 Jun 22 | 8 | -100 | 42 | 53 |
| 31 Mar 22 | 15 | -94 | 38 | 52 |
| 31 Dec 21 | 13 | -92 | 36 | 51 |
| 30 Sep 21 | 12 | -103 | 29 | 75 |
| 30 Jun 21 | 7 | -81 | 23 | 61 |
| 31 Mar 21 | 0 | -73 | 22 | 52 |
| 31 Dec 20 | 0 | -62 | 19 | 45 |
Quality Earnings: AEGIR is currently unprofitable.
Growing Profit Margin: AEGIR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AEGIR is unprofitable, and losses have increased over the past 5 years at a rate of 50.5% per year.
Accelerating Growth: Unable to compare AEGIR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AEGIR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: AEGIR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.